Compare Duolingo Inc (DUOL) vs GSK plc (GSK) Price & Performance

Duolingo (DUOL) trades at $150.50, down 0.8% on the day, as the stock consolidates near key resistance at $151. The company demonstrates strong fundamental momentum with revenue reaching $1.04 billion in 2025 and net income surging to $414 million, representing a robust 39.9% margin. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $0.66 exceeding the $0.604 forecast. Technical indicators show a bullish moving average alignment while RSI levels suggest potential near-term consolidation.

Duolingo presents a compelling growth story with accelerating profitability and strong user engagement, though valuation multiples remain elevated. Key risks include increased competition in edtech and insider selling activity. Analyst consensus leans cautious with a $140.63 price target below current levels, suggesting potential near-term headwinds despite the company's operational excellence.

GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.

GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.